Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05686551 · ClinicalTrials.gov registry record · Phase 2
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
A Phase 2 study of Huntington Disease, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
- 20
- Study locations
NCT05686551: Active Phase 2 study of Huntington Disease, sponsored by Hoffmann-La Roche.
NCT05686551 is a Phase 2 study of Huntington Disease that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 301 participants, below the 627-participant average among 35 other Huntington Disease trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05686551, a Phase 2 study of Huntington Disease, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tominersen
Study Locations (20)
Florida
- University of Florida - Gainesville
- University of South Florida - Tampa
Washington
- EvergreenHealth Investigational Drug Services - Kirkland
- Inland Northwest Research - Spokane
Other
- CINME - Buenos Aires
- Hospital Ramos Mejía - CABA
Alabama
- Uab Medicine - Birmingham
Arizona
- Barrow Neurological Institute - Phoenix
California
- University of California Davis Medical System - Sacramento
Colorado
- CenExel Rocky Mountain Clinical Research, LLC - Englewood
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2023-02-03 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 2 |
What the registry record for NCT05686551 still lists
NCT05686551 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 627-participant average among 35 other Huntington Disease trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05686551 names 20 study sites across 17 states, led by Florida, Washington, Other.
Frequently Asked Questions
What is clinical trial NCT05686551 about?
NCT05686551 is a clinical study titled "GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease". This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).
What is the current status of trial NCT05686551?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2023-02-03. Estimated completion is 2027-04-01.
What conditions does trial NCT05686551 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT05686551?
The interventions under investigation include: Placebo (DRUG), Tominersen (DRUG).
Who is sponsoring clinical trial NCT05686551?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05686551 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05686551's enrollment target sits among peer trials
301 11th of 35 higher than 25 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
ACTIVE NOT RECRUITING · Phase 2
-
Creatine Safety and Tolerability in Premanifest HD: PRECREST
COMPLETED · Phase 2
-
Atomoxetine and Huntington's Disease
COMPLETED · Phase 2
-
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
COMPLETED · Phase 2
-
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI